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The aim of this study was to evaluate the efficacy of tacrolimus eye drops 
in alleviating the clinical symptoms of canine keratoconjunctivitis sicca (KCS) 
and to compare this efficacy with that of cyclosporine. The clinical study was 
conducted on 40 dogs diagnosed with idiopathic KCS. The dogs were divided into 
two groups of 20 animals each. In Group I, 0.75% cyclosporine eye drops were 
administered three times a day, while in Group II 0.02% tacrolimus eye drops 
were given twice daily. In addition, each group was subdivided into three sub-
groups based on the results of Schirmer tear test I (STT I). Clinical and ophthal-
mologic examinations were performed prior to the treatment as well as after one 
and two months of therapy. The application of both tacrolimus and cyclosporine 
resulted in a significant reduction of neovascularisation after the first and second 
month of treatment (P < 0.05, P < 0.001); however, in moderate and advanced 
stages, the observed efficacy of tacrolimus was higher. Across all patients, a sig-
nificant increase in STT I values was observed after both the first and second 
month of treatment with tacrolimus (P < 0.01), as well as after two months of 
treatment with cyclosporine (P < 0.05). In both groups, some patients were ob-
served to exhibit inhibited development of pigmentation, but an analysis of par-
ticular clinical cases and statistical data revealed no statistically significant dis-
crepancies in the course of the study. In cases of advanced canine KCS, the effi-
cacy of tacrolimus may be higher than that of cyclosporine.  
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Keratoconjunctivitis sicca (KCS) is an eye disease involving a disorder in 
tear production and/or incorrect composition of the tear film. Untreated or incor-
rectly treated KCS may lead to eyesight impairment, even blindness (Aguirre et 
al., 1971; Kaswan et al., 1985; Bartnett, 1997; Balicki et al., 2008; Bonagura and 
Twedt, 2009). In most clinical cases, immune-mediated KCS is diagnosed, in-
volving infiltration by mononuclear cells and atrophy of the glandular tissue of 
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lacrimal glands, which results in a decrease or complete cessation of secretory 
activity (Kaswan et al., 1984; Whitley et al., 1991). 
The first noticeable symptoms include conjunctival redness, abnormal 
contraction of the eyelid (blepharospasm), and the presence of exudate in the 
conjunctival sac (Miller, 2008). 
One of the typical KCS symptoms is the presence in the conjunctival sac 
of a mucous, mucopurulent or purulent, often sticky exudate. Dogs suffering 
from KCS tend to suffer from disorders of corneal transparency. The improperly 
moistened cornea loses its shininess and becomes opaque. As a result of the in-
flammation the cornea becomes swollen, which further reduces its transparency, 
and vascular ingrowth occurs. This is often accompanied by photophobia. An-
other characteristic symptom of KCS is corneal pigmentation (Kaswan et al., 
1995). As the disease progresses, the swelling, vascular ingrowth and pigmenta-
tion spread to a growing area of the cornea, leading to eyesight deterioration, and 
in extreme cases to blindness (Kaswan et al., 1995). In the absence of a tear film, 
corneal epithelial defects occur, followed by ulceration. Ulcers are typically lo-
cated in the centre of the cornea (Kaswan et al., 1995; Miller, 2008). 
The diagnosis of KCS is based on data collected from interviews, recogni-
tion of clinical symptoms, and results of the Schirmer tear test (STT) (Trbolova, 
2005; Miller, 2008). STT results below 15 mm/min are considered inadequate 
and an indication of KCS. Three stages of KCS advancement can be identified 
based on the STT value (Giuliano and Moore, 2007): early or subclinical stage of 
KCS – STT 11–14 mm/min; moderate or mild stage of KCS – STT 6–10 mm/min; 
severe stage of KCS – STT 0–5 mm/min. 
The treatment of KCS is primarily based on cyclosporine (CsA), applied 
in the form of drops diluted in castor oil, corn oil, rape oil, or olive oil in concen-
trations ranging from 0.5% to 2%, as well as ready-made 0.2% ophthalmologic 
ointment (Optimune, MSD Animal Health) (Kaswan et al., 1989; Morgan and 
Abrams, 1991). One of the first studies on the use of cyclosporine in KCS treat-
ment was published by Kaswan et al. (1989), who attempted to treat KCS with 
2% cyclosporine in corn oil. In the course of the therapy, the STT results im-
proved by 5 mm/min or more in 59% of the animals. After several months of 
treatment, corneal neovascularisation and pigmentation were reduced. Herrera 
and Lightowler (1994) conducted a study in which patients with STT results be-
tween 6 and 10 mm were treated with 2% cyclosporine, and were able to report 
return to the normal STT range in 93.6% of the cases. They also observed return 
to the original STT value in 80.5% of patient whose STT value at the beginning 
of the treatments was between 2 and 6 mm. However, patients whose STT value 
was not increased still showed an improvement in terms of the clinical condition 
of the cornea and conjunctiva. Another study confirmed the high efficacy of a 
1% solution of cyclosporine in olive oil administered to patients suffering from 
KCS once every twelve hours. The therapy was conducted on 22 dogs for a pe-
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riod of 4 weeks. An increase in STT results of 5 mm or more was observed in 
86.4% of the patients, while improvement in terms of clinical symptoms was re-
ported in 81.8% of the dogs (Olivero et al., 1991). The treatment of KCS also in-
cluded the use of a newly developed aqueous calcineurin inhibitor, SCY-641. It 
is a semi-synthetic derivative of cyclosporine which was used in the course of 
KCS treatment in the form of 0.03% eye drops. The use of SCY-641 in sick dogs 
resulted in significantly higher STT than that observed in placebo-treated dogs 
(Gilger et al., 2013). 
Another compound with characteristics and activity mechanisms similar to 
those of cyclosporine is tacrolimus. It is a macrolide antibiotic isolated from 
Streptomyces tsukubaensis. Its immunomodulatory effect is similar to that of 
CsA (Kino et al., 1987; Kilmartin et al., 1998). Berdoulay et al. (2005) used a 
0.02% water solution of tacrolimus, administered twice daily, in the treatment of 
105 dogs suffering from KCS. Animals qualified for the study were dogs that 
had not undergone prior stimulation of tear secretion, dogs successfully treated 
with cyclosporine, as well as animals for whom cyclosporine treatment proved 
ineffective. An increase in STT results by 5 mm/min or more was reported in 
85% of the previously untreated animals and in 51% of animals previously un-
successfully treated with cyclosporine. In all dogs with a reported good response 
to cyclosporine, the treatment change to tacrolimus was successful and rendered 
the same therapeutic effect. Apart from the change in the STT value, an im-
provement in terms of clinical symptoms was also observed. Despite failing to 
evaluate the degree of corneal pigmentation and vascularisation, the authors re-
ported a significant clinical improvement. No hypersensitivity to tacrolimus was 
observed, which suggests that this treatment can be administered to animals with 
a low tolerance to cyclosporine. 
The aim of this study was to evaluate the efficacy of KCS treatment with 
0.75% cyclosporine eye drops in comparison to treatment with 0.02% tacrolimus 
eye drops administered for a period of two months. 
 
 
Materials and methods 
Animals qualified for the study included 40 dogs of various breeds includ-
ing mixed-breed dogs, 21 females and 19 males, aged between 1 and 13 years, 
diagnosed with idiopathic KCS and previously untreated for the disease (Tables 
1 and 2). The patients underwent detailed ophthalmic examinations using a slit 
lamp as well as indirect and direct ophthalmoscopy. Schirmer tear test I values 
were determined with the use of standard strips (Schering Plough Animal Health). 
All dog owners were comprehensively interviewed. The dogs were also sub-
jected to thorough clinical examination in order to exclude other diseases. In all 
dogs, complete blood cell count tests were conducted using a URIT-2900 Vet 
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apparatus (Guilin Botest Medical Electronic Co. Ltd.). Serum biochemical pro-
files were performed to determine the activities of alanine transaminase, alkaline 
phosphatase and aspartate transaminase, as well as the levels of urea, complete 
bilirubin, creatinine and glucose using a Rayto RT-1904 VET apparatus (Rayto 
Electronics Inc.). The dogs showed no clinical symptoms other than ophthal-
mological signs, as confirmed by the haematological and biochemical tests per-
formed. Animals diagnosed with hypothyroidism were excluded from the study. 
Table 1 
Breed, sex and age of dogs in Group I 
Patient  
number Breed Sex 
Age  
(years) 
Subgroup I 
1 Poodle ♀ 12 
2 Pug ♂ 5 
3 Poodle ♂ 9 
4 Yorkshire Terrier ♀ 12 
5 Yorkshire Terrier ♂ 1 
6 Chow Chow ♂ 6 
Subgroup II 
1 Yorkshire Terrier ♀ 3.5 
2 French Bulldog ♂ 5 
3 Shih-Tzu ♂ 2 
4 West Highland White Terrier ♀ 6 
5 Pekingese ♂ 8 
6 Yorkshire Terrier ♂ 4 
7 Shih-Tzu ♀ 2 
Subgroup III 
1 Shih-Tzu ♀ 1 
2 Poodle ♂ 12 
3 Siberian Husky ♂ 4 
4 Labrador ♂ 5 
5 Miniature Schnauzer ♂ 6 
6 Yorkshire Terrier ♀ 1.5 
7 Poodle ♀ 10 
 
The dogs were divided into two study groups based on the type of treat-
ment received. In Group I, 20 animals were treated with cyclosporine (0.75% eye 
drops) administered three times a day. 
In Group II, 20 animals were treated with tacrolimus (0.02% eye drops) 
administered twice a day. 
Furthermore, each group was subdivided into three subgroups on the basis 
of the STT I results: subgroup I (6 dogs) – STT I values between 0 and 5, sub-
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group II (7 dogs) – STT I values between 6 and 10, and subgroup III (7 dogs) – 
STT I values between 11 and 14. In two Group I animals and three Group II 
animals the disease was unilateral. 
Table 2 
Breed, sex and age of patients in Group II 
Patient  
number Breed Sex 
Age  
(years) 
Subgroup I 
1 Chow Chow ♂ 3.5 
2 Cocker Spaniel ♀ 4 
3 Pekingese ♀ 9 
4 Miniature Schnauzer ♂ 8 
5 Yorkshire Terrier ♀ 4 
6 Pug ♂ 7 
Subgroup II 
1 Shih-Tzu ♀ 2 
2 Chow Chow ♂ 1 
3 Golden Retriever ♀ 7 
4 Shih-Tzu ♀ 2 
5 Yorkshire Terrier ♂ 3 
6 Mix breed ♀ 13 
7 Poodle ♂ 12 
Subgroup III 
1 Cocker Spaniel ♀ 1 
2 Poodle ♂ 5 
3 Chow Chow ♂ 1 
4 Yorkshire Terrier ♂ 3 
5 Mix breed ♀ 7 
6 Labrador ♀ 11 
7 Poodle ♀ 10 
 
Where purulent exudate was observed in the conjunctival sac, patients re-
ceived 0.3% ofloxacin in the form of eye drops (Floxal, Dr Mann Pharma) ad-
ministered four times daily for a period of two weeks. If the purulent exudate 
persisted, the patients received a 2-week treatment with 0.3% tobramycin drops 
(Tobrosopt, Polfa S.A) administered four times daily. In cases of corneal ulcera-
tion, dexpanthenol (Corneregel, Dr Mann Pharma) was additionally administered 
three times a day. 
Clinical signs were evaluated as follows: conjunctival hyperaemia (score 
0: no conjunctival hyperaemia, 1: mild hyperaemia, 2: moderate hyperaemia, 3: 
significant hyperaemia), ocular discharge (score 0: no ocular discharge, 1: small 
amount of mucous exudate in the conjunctival sac; 2: mucopurulent exudate pre-
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sent in the medial canthus, 3: purulent exudate present along the lower eyelid 
margin, 4: purulent exudate present on the eyelids and in the vicinity of the eye 
socket), area of corneal pigmentation (score 0: no corneal pigmentation, 1: pig-
mentation over less than 25% of the cornea, 2: pigmentation over 25–50% of the 
cornea, 3: pigmentation over 50–75% of the cornea, 4: pigmentation over > 75% 
of the cornea), corneal transparency (score 0: full transparency, 1: reduced trans-
parency – iris poorly visible, 2: lack of transparency), vascular ingrowth in par-
ticular corneal quadrants (score 0: no corneal vessels, 1: vascular ingrowth in one 
corneal quadrant, 2: vascular ingrowth in two corneal quadrants, 3: vascular in-
growth in three corneal quadrants, 4: vascular ingrowth in four corneal quad-
rants), corneal defect (score 0: no corneal defect, 1: corneal defect stained by 
fluorescein). 
Ophthalmic examinations were conducted prior to the treatment, as well as 
after one and two months of therapy. The degree of corneal neovascularisation 
and pigmentation was assessed on the basis of photographs. 
The study utilised two types of statistical data: numerical (quantitative) 
and qualitative. The results obtained from Schirmer tear test I were checked for 
normal distribution on a Gaussian curve. For this purpose, the Shapiro–Wilk test 
was applied, which did not confirm normal distribution. For that reason, results 
were interpreted by calculating the median, maximum and minimum values. In 
the case of qualitative data pertaining to vascular ingrowth and pigmentation, the 
results were quantified by considering the number of quadrants affected by ne-
ovascularisation and the number reflecting the degree of pigmentation. In assess-
ing the degree of neovascularisation and pigmentation, Pearson’s non-parametric 
χ2 (chi-squared) independence test was used, which is suitable for analyses of 
qualitative data. Statistical analyses were conducted for groups considered as a 
whole, without accounting for group subdivisions. 
 
 
Results 
Data obtained from the animals’ owners revealed that in four dogs cyc-
losporine eye drops caused irritation as indicated by the animals’ tendency to rub 
the area of the eye socket shortly after administration. The effect ceased after sev-
eral minutes. The owners also reported that the dogs which initially showed side 
effects would gradually become used to the eye drops over a 2- to 3-week period 
of therapy, and the irritation would eventually cease or become less intensive. 
In both groups, the observed regression of clinical symptoms was gradual, 
with the individual response to treatment varying between particular animals. In 
the case of two conjunctival sacs in Group I and 4 in Group II, the degree of con-
junctival redness did not change over the entire course of treatment. Moreover, in 
one patient treated with tacrolimus, the degree of conjunctival redness decreased 
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after the first month but returned to the original level at the end of the 2-month 
therapy. In other patients from both groups the administered treatments resulted 
in a reduction of conjunctival redness. 
Before treatment in Group I, 3rd degree purulent exudate was observed in 
17 conjunctival sacs, 4th degree in 10, 2nd degree in 9, and 1st degree in 2. In 
Group II, before treatment, 3rd degree purulent exudate was present in 19 con-
junctival sacs, 4th degree in 9, and 2nd degree in 9. The administered treatment 
resulted in a reduction of conjunctival sac exudation. After one month of tac-
rolimus treatment, exudation in 33 of 37 conjunctival sacs was reduced, and the 
effect extended to all conjunctival sacs after the second month of therapy. In the 
group treated with cyclosporine, improvement in terms of exudation was ob-
served in 30 out of 38 affected conjunctival sacs after the first month, and 34 af-
ter 2 months of treatment. At the end of the two-month treatment no patient in ei-
ther group was diagnosed with 4th degree conjunctival sac purulent exudation. 
Third degree purulent exudation persisted in 4 conjunctival sacs in Group I and 2 
in Group II. In the remaining patients, 1st and 2nd degree mucous exudation was 
observed. In 3 conjunctival sacs in Group I and 5 in Group II no exudation was 
present. 
The results of Schirmer tear test I during the treatment of KCS in Groups I 
and II were presented in Tables 3 and 4. A statistically significant increase in the 
STT I value was observed after two months of treatment with cyclosporine and 
in both the first and second month of treatment with tacrolimus (Table 5). An in-
crease in STT I values of 5 mm/min or more was observed in 11 conjunctival sacs 
after one month of treatment and in 21 after two months of treatment in Group II, 
compared to 6 conjunctival sacs after one month and 15 after two months of 
treatment in Group I. In subgroup I of Group I, after one month of treatment an 
STT I value increase of 5 mm/min or more was observed in 2 conjunctival sacs 
and after two months in 5 sacs, compared to a respective 5 mm/min increase in 4 
conjunctival sacs after one month and 7 after two months of treatment in Group 
II. In subgroup II of Group I, an increase in STT I values of 5 mm/min or more 
was observed in 2 conjunctival sacs after one month and 6 after two months of 
treatment, compared to a respective STT I increase by 5 mm/min or more in 6 
conjunctival sacs after one month and 10 after two months recorded in Group II. 
A STT I increase of 5 mm or more in respective subgroups III was observed in 2 
conjunctival sacs in Group I and 1 in Group II after the first month of treatment, 
and in 4 conjunctival sacs in either group after the second month of therapy. In 
one Group I case no STT I increase was observed throughout the treatment. 
Moreover, in 2 cases of Group I and 2 cases of Group II, the STT I values de-
creased compared to the values recorded prior to the treatment. In yet another pa-
tient in the group receiving cyclosporine, the STT I value remained at 0 through-
out the therapy. 
320 RADZIEJEWSKI and BALICKI 
Acta Veterinaria Hungarica 64, 2016 
Table 3 
Results of Schirmer tear test I during the treatment of keratoconjunctivitis sicca (KCS) in Group I 
Result of Schirmer tear test I (mm) 
Before treatment After 1 month of treatment After 2 months of treatment Patient  number 
Right eye Left eye Right eye Left eye Right eye Left eye 
Subgroup I 
1 5 4 8 7 9 7 
2 2 5 5 10 6 11 
3 4 4 6 8 9 10 
4 5 4 4 3 2 1 
5 – 0 – 0 – 0 
6 5 5 9 11 12 14 
Subgroup II 
1 9 10 14 14 14 16 
2 8 9 12 13 14 14 
3 7 6 9 10 11 10 
4 6 10 8 11 9 12 
5 9 8 10 11 11 10 
6 10 9 13 13 14 13 
7 6 9 12 13 14 14 
Subgroup III 
1 11 13 16 17 16 15 
2 12 11 9 10 9 8 
3 12 11 14 11 15 12 
4 14 13 14 14 15 14 
5 11 12 15 14 16 14 
6 – 11 – 14 – 15 
7 12 13 17 16 19 20 
 
After one month of treatment, an increase in transparency was observed in 
13 of 31 corneas in Group I and 11 of 27 corneas in Group II. After the subse-
quent month, an increase in transparency was recorded in another 4 corneas in 
Group I and 9 in Group II. After two months of treatment, an improvement in 
terms of transparency was observed in a total of 17 of 31 corneas in Group I and 
20 of 27 corneas in Group II. 
The use of tacrolimus or cyclosporine in the treatment of KCS resulted in 
a statistically significant decrease in vascular ingrowth after both the first and 
second month of therapy; however, tacrolimus therapy decreased corneal ne-
ovascularisation in a higher number of quadrants (Tables 6 and 7). An analysis of 
vascular ingrowth revealed a higher efficacy of tacrolimus in subgroup I, where 
the symptoms were the most intensive, with a decrease in corneal neovasculari-
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sation observed in 6 corneas after one month and 7 corneas after two months of 
treatment, compared to subgroup I of Group I where the same was observed in 4 
corneas after one month and 5 corneas after two months of therapy. In subgroup 
II, the discrepancy between the particular preparations in terms of efficacy in 
countering corneal neovascularisation was even more apparent. Of 11 corneas af-
fected by vascular ingrowth, improvement was observed in 3 corneas after one 
month and 9 corneas after two months of treatment with cyclosporine. By com-
parison, in the group receiving tacrolimus, improvement was observed in 8 out of 
10 corneas after the first month, and in all affected corneas after two months of 
therapy. In subgroup III, after two months of treatment with either tacrolimus or 
cyclosporine, reduced corneal neovascularisation was observed in all patients 
from both groups. 
Table 4 
Results of Schirmer tear test I during the treatment of keratoconjunctivitis sicca (KCS) in Group II 
Result of Schirmer tear test I (mm) 
Before treatment After 1 month of treatment After 2 months of treatment Patient  number 
Right eye Left eye Right eye Left eye Right eye Left eye 
Subgroup I 
1 3 5 14 13 13 13 
2 4 3 8 9 9 10 
3 2 2 1 1 1 0 
4 4 5 4 3 2 3 
5 0 – 4 – 5 – 
6 5 4 9 9 11 10 
Subgroup II 
1 10 7 17 15 18 16 
2 8 – 12 – 15 – 
3 6 8 11 12 13 14 
4 6 6 8 9 10 10 
5 8 9 11 14 12 14 
6 6 8 9 11 11 13 
7 9 8 14 16 15 16 
Subgroup III 
1 13 14 16 16 15 14 
2 12 – 16 – 17 – 
3 14 11 18 17 19 19 
4 12 11 13 12 13 13 
5 12 13 14 15 14 15 
6 11 11 13 12 14 14 
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Table 5 
Results of Schirmer tear test I 
Result of Schirmer tear test I (mm) 
Median (minimum–maximum values) 
Before treatment After 1 month of treatment After 2 months of treatment  
Right eye Left eye Right eye Left eye Right eye Left eye 
Group I 8.5 
(2–14) 
9.0 
(0–13) 
11.0 
(4–17) 
11.0 
(0–17) 
13.0* 
(2–19) 
12.5* 
(0–20) 
Group II 8.0 
(0–14) 
8.0 
(2–14) 
12.5** 
(1–18) 
12.0** 
(1–17) 
13.0** 
(1–19) 
14.0** 
(0–19) 
Statistically significant differences: *P < 0.05; **P < 0.01 
 
Table 6 
Assessment of vascular ingrowth and corneal pigmentation in Group I 
 Before treatment After 1 month  of treatment 
After 2 months  
of treatment 
 Right eye Left eye Right eye Left eye Right eye Left eye 
Number of corneal quad-
rants affected by neovas-
cularisation 
 
 
38 
 
 
44 
 
 
28* 
 
 
27*** 
 
 
19* 
 
 
16*** 
Degree of corneal pig-
mentation  
 
26 
 
24 
 
22 
 
20 
 
19 
 
16 
Statistically significant differences: *P < 0.05; ***P < 0.001 
 
Table 7 
Assessment of vascular ingrowth and corneal pigmentation in Group II 
 Before treatment After 1 month  of treatment 
After 2 months  
of treatment 
 Right eye Left eye Right eye Left eye Right eye Left eye 
Number of corneal quad-
rants affected by neovas-
cularisation 
 
 
51 
 
 
34 
 
 
24*** 
 
 
24* 
 
 
12*** 
 
 
14* 
Degree of corneal pig-
mentation  
 
22 
 
21 
 
21 
 
18 
 
14 
 
15 
Statistically significant differences: *P < 0.05; ***P < 0.001 
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Fig. 1. Right eye of a 6 years old male Chow Chow (patient no. 6 from Subgroup I of Group I) 
treated with cyclosporine. Top: At presentation. Schirmer tear test (STT) = 5, conjunctival  
hyperaemia – score 2, ocular discharge – score 4, corneal pigmentation – score 4, corneal  
transparency – score 1, corneal neovascularisation – score 4, corneal defect – score 0.  
Bottom: After 8 weeks of treatment. Schirmer tear test (STT) = 12, conjunctival hyperaemia – 
score 1, ocular discharge – score 2, corneal pigmentation – score 1, corneal transparency – score 0, 
corneal neovascularisation – score 1, corneal defect – score 0 
In both groups, some patients were observed to exhibit inhibited develop-
ment of pigmentation but an analysis of particular clinical cases and statistical 
data revealed no statistically significant discrepancies in the course of the study 
(Tables 6 and 7). Treatment with both tacrolimus and cyclosporine led to a re-
duction of pigmentation in certain, most advanced cases (Fig. 1). In subgroup I 
of Group I, out of 9 corneas affected by pigmentation during the course of the 
study, improvement was observed in 4 cases; by comparison, in Group II, im-
provement was also observed in 4 corneas, although the total number of corneas 
affected by pigmentation prior to the study was 10. In one patient treated with 
tacrolimus, after the first month, the degree of pigmentation decreased but then 
returned to the pre-treatment state after two months of therapy. 
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Fig. 2. Right eye of a 12 years old male Poodle (patient no. 7 from Subgroup II of Group II) treated 
with tacrolimus. Top: At presentation. Schirmer tear test (STT) = 9, conjunctival hyperaemia – 
score 3, ocular discharge – score 3, corneal pigmentation – score 0, corneal transparency – score 1, 
corneal neovascularisation – score 4, corneal defect – score 1. Bottom: After 8 weeks of treatment. 
Schirmer tear test (STT) = 15, conjunctival hyperaemia – score 1, ocular discharge – score 2,  
corneal pigmentation – score 0, corneal transparency – score 0, corneal neovascularisation – score 0, 
corneal defect – score 0 
The administered treatment led to adequate healing of corneal ulceration 
within the first month of therapy (Fig. 2), the only exceptions being defects in 
one patient in subgroup I of Group I, and one patient in subgroup II of Group I, 
where healing was observed after two months. 
 
 
Discussion 
Keratoconjunctivitis sicca is an eye disease which may lead to significant 
eyesight impairment. Despite the high efficacy of cyclosporine in KCS treatment 
some patients can be resistant to its effects, which is why research is continu-
ously under way with the aim of finding alternative treatment methods (Cham-
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bers et al., 2002). Few publications are available on the use of tacrolimus in the 
treatment of KCS. To date, there has been no in-depth comparative research into 
the efficacy of tacrolimus and cyclosporine in the treatment of immunological 
KCS. In the present study, 0.02% tacrolimus was administered twice daily and 
its efficacy was compared to 0.75% cyclosporine administered in the standard 
dosage, three times a day. The concentration and frequency of tacrolimus ad-
ministration were in line with the results obtained by Berdoulay et al. (2005). 
Cyclosporine significantly reduces exudation and conjunctival hyperaemia 
(Sansom et al., 1995). In the present study, a gradual decrease of exudation and 
conjunctival redness was observed in the course of both treatments. However, 
based on the specific results pertaining to eliminating exudation, tacrolimus can 
be reported to show greater effectiveness than cyclosporine. In dogs treated with 
tacrolimus, the amount of exudate was reduced in 100% of the patients after the 
2-month therapy, whereas in the group treated with cyclosporine the amount of 
exudate present in 3 conjunctival sacs persisted at the same level throughout the 
treatment. It is also important to notice that high efficacy of the tested prepara-
tions was also demonstrated in patients with advanced clinical symptoms of the 
disease. In an earlier study by Berdoulay et al. (2005), the researchers reported a 
significant reduction of exudation and reduced conjunctival redness after admin-
istering tacrolimus. Moreover, the authors observed improvement in terms of 
these symptoms also in a group of patients previously unsuccessfully treated 
with cyclosporine. 
Numerous studies indicate that cyclosporine is highly effective in treating 
canine KCS. It alleviates the clinical symptoms and improves the STT results 
(Kaswan et al., 1989; Morgan and Abrams, 1991; Olivero et al., 1991; Herrera 
and Lightowler, 1994). As the quoted authors used cyclosporine in various con-
centrations, in the form of either ointment or drops, the reported STT improve-
ment varied accordingly. Kaswan et al. (1989) administered 2% cyclosporine in 
the treatment of KCS and reported an increase in STT values of 5 mm or more in 
59% of the patients. In another study, Morgan and Abrams (1991) reported an 
increase of STT results in 60% of patients with initial STT values within the 
range from 0 to 2 mm, and in 90–92% in dogs with an initial STT of over 3 mm/ 
min. Furthermore, the authors observed a significant regression of clinical symp-
toms, which brought considerable relief to the patients and improved their eye-
sight. Cyclosporine was also successfully used in different concentrations. 
Herrera and Lightowler (1996) used 0.2% ophthalmic ointment in the treatment 
of KCS and reported an average STT improvement of 10 mm/min after a 28-day 
therapy. In yet another study, the authors administered eye drops containing 1% 
cyclosporine and reported an increase in STT results of 5 mm/min or more in 
86% of the cases (Olivero et al., 1991). In the present study, an increase in STT 
results was observed both for cyclosporine and tacrolimus. Similarly, in the re-
search by Hendrix et al. (2011), increased STT values were reported in both a 
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group of dogs receiving 0.03% tacrolimus eye drops and a group receiving 2% 
cyclosporine, without statistically significant discrepancies between the two. A 
greater increase in STT values was observed after administering 1% pimecrolimus 
when compared to 0.2% cyclosporine (Ofri et al., 2009). In a short-term study 
conducted by Berdoulay et al. (2005) it was reported that in patients suffering 
from KCS and successfully treated with cyclosporine, it was possible to replace 
the preparation with tacrolimus and maintain the same results. Furthermore, the 
authors observed 51% efficacy of tacrolimus in patients either entirely unrespon-
sive to cyclosporine or showing only very weak response to the drug. In the pre-
sent study, tacrolimus was also observed to be more effective than cyclosporine, 
confirming the results obtained by Berdoulay et al. (2005). In the course of a 
two-month therapy, an increase in STT I results of 5 mm/min or more was ob-
served in 21 out of 37 conjunctival sacs in the group of dogs treated with tac-
rolimus, compared to 15 out of 38 conjunctival sacs in the group treated with 
cyclosporine. It should be emphasised that both in the case of tacrolimus and 
cyclosporine, certain cases were recorded where STT results decreased. The 
same may be attributed to the progressing atrophy of lacrimal glands and the re-
lated lack of responsiveness to tear production stimulants. 
It is believed that KCS in Yorkshire Terriers may be congenital. However, 
immune-mediated KCS can affect this breed as much as any other dog. Lacrimal 
gland aplasia or hypoplasia should be considered in young dogs with severe uni-
lateral ocular dryness (Herrera et al., 2007; Westermeyer et al., 2009). In the pre-
sent study, unilateral KCS was diagnosed in one dog aged 4 years and in two 
younger animals aged 1 and 1.5 years, respectively. It is believed that when con-
genital alacrima is suspected, cyclosporine treatment should be administered as it 
tends to yield a better prognosis (Westermeyer et al., 2009). In the present study 
the cyclosporine treatment yielded no improvement in two Yorkshire Terrier 
dogs from Group I (a one-year-old male with unilateral KCS and a 12-year-old 
female with bilateral KCS), while in three other animals, an increase in STT I 
values and regression of clinical symptoms were observed. In Group II, in all 
dogs treated with tacrolimus, an increase in STT I values and regression of clini-
cal symptoms were observed. It can be assumed that the one-year-old Yorkshire 
Terrier patient from Group I (patient no. 5 from subgroup I showing no signs of 
improvement after the administration of cyclosporine treatment) may have suf-
fered from congenital alacrima. 
Earlier studies demonstrated high efficacy of cyclosporine in inhibiting 
vascular ingrowth in patients suffering from KCS (Olivero et al., 1991). How-
ever, the available literature does not provide information on the efficacy of tac-
rolimus with regard to limiting corneal neovascularisation in KCS patients. In the 
present study, inhibition of vascular ingrowth was observed in both study groups, 
although in the case of advanced and intermediate disease stages the efficacy of 
tacrolimus in this respect was demonstrably higher when compared to cyc-
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losporine. The same was evidenced by a greater number of corneal quadrants and 
corneas where neovascularisation was observed to have been reduced as a result 
of the therapy. Regression of corneal neovascularisation is an important element 
of KCS treatment, as by reducing the number of ingrown blood vessels, corneal 
transparency is improved and pigmentation reduced, which significantly im-
proves the patients’ eyesight. 
Reduction of pigmentation is among the most challenging aspects of treat-
ing chronic keratitis. Morgan and Abrams (1991) observed a 67% reduction of 
pigmentation when using cyclosporine treatment. Corneal pigmentation was also 
reduced in a several months long KCS treatment with cyclosporine (Olivero et 
al., 1991). The present study does not confirm the alleged high efficacy of cyc-
losporine in eliminating corneal pigmentation in dogs suffering from KCS. In 
several patients the development of pigmentation was inhibited but pigmentation 
as such was not reduced, as evidenced by an analysis of individual clinical cases 
and statistical data. The available literature does not mention the efficacy of tac-
rolimus with regard to limiting pigmentation in KCS patients. Berdoulay et al. 
(2005) only mention that an improvement in terms of pigmentation and neovas-
cularisation was reported by the owners within 10–14 days of initiating the 
treatment. In the present study, no cases were observed where further progres-
sion of pigmentation would occur despite the treatment, either in the tacrolimus 
or in the cyclosporine groups. The only exception was one patient treated with 
tacrolimus, where after the first month the degree of pigmentation was decreased 
but returned to the pre-treatment state after the second month of therapy. The 
lack of significant improvement in terms of pigmentation may also result from 
the stage of advancement of the clinical symptoms. The same is suggested by the 
results obtained in the present study, where some patients diagnosed with sub-
clinical KCS showed a reduction in the extent of pigmentation when treated with 
either tacrolimus or cyclosporine. In more advanced stages, where corneal pig-
mentation was more common, with the exception of certain isolated cases the 
degree of pigmentation remained unchanged throughout the treatment. There-
fore, the obtained results indicate that the use of both tacrolimus and cyc-
losporine may inhibit further development of pigmentation in KCS patients but 
rarely causes reduction of the same. 
In the present study, in all dogs treated with cyclosporine the corneal de-
fects healed during the two-month treatment. Earlier studies by Sansom et al. 
(1995) also reported healing of corneal ulcerations in cases of canine KCS. Out 
of 41 damaged corneas, 26 healed in the course of a 42-day therapy. In the pre-
sent study, all observed corneal defects healed already in the first month of 
treatment but the mechanism of healing corneal ulcerations in KCS cases treated 
with tacrolimus requires further research. 
The present research revealed no side effects, neither systemic nor local, 
resulting from receiving 0.02% tacrolimus eye drops. Cases of irritation caused 
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by cyclosporine have been reported in the literature (Sansom et al., 1995). Izci et 
al. (2002) mentioned irritative effects of the preparation in some patients, which 
tended to subside within the first 10 days of treatment as the clinical symptoms 
of the disease were alleviated. In the present study, 4 patients were reported to 
have suffered mild irritation in response to the medicine, as evidenced by the at-
tempts to rub the vicinity of the eye socket. Such side effects were not observed 
for tacrolimus. The mentioned irritative effects of cyclosporine eye drops were 
short lasting (not longer than several minutes after administration), and did not 
influence the course of the study. Moreover, in most patients the tendency to rub 
of the orbital region would eventually cease or become less intensive within 2–3 
weeks from the beginning of the treatment. 
To recapitulate the obtained results, it should be concluded that tacrolimus 
may be used in the treatment of all clinical stages of canine KCS. In advanced 
stages of canine KCS tacrolimus may indeed prove more effective than cyc-
losporine.  
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